Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1984 1
1990 1
1991 4
1992 2
1993 1
1994 3
1995 1
1996 4
1997 4
1999 1
2000 2
2001 2
2002 1
2004 4
2005 7
2006 2
2007 3
2008 5
2009 5
2010 7
2011 4
2012 6
2013 8
2014 3
2015 5
2016 4
2017 2
2018 2
2019 5
2020 2
2021 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Pfisterer J, et al. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Lancet Oncol. 2020. PMID: 32305099 Free article. Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Deciphering morphology in Triatominae: the evolutionary signals.
Dujardin JP, Costa J, Bustamante D, Jaramillo N, Catalá S. Dujardin JP, et al. Among authors: catala s. Acta Trop. 2009 May-Jun;110(2-3):101-11. doi: 10.1016/j.actatropica.2008.09.026. Epub 2008 Nov 5. Acta Trop. 2009. PMID: 19026978 Review.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM; PHARE trial investigators. Pivot X, et al. Among authors: catala s. Lancet. 2019 Jun 29;393(10191):2591-2598. doi: 10.1016/S0140-6736(19)30653-1. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178155 Clinical Trial.
Antennal sensilla of Rhodnius.
Catalá S, Schofield C. Catalá S, et al. J Morphol. 1994 Feb;219(2):193-203. doi: 10.1002/jmor.1052190208. J Morphol. 1994. PMID: 29865357
Maintaining professional activity during breast cancer treatment.
Ganem G, Antoine EC, Touboul C, Naman H, Dohollou N, Facchini T, Coscas Y, Lortholary A, Catala S, Jacquot S, Lhomel C, Eisinger F. Ganem G, et al. Among authors: catala s. Eur J Cancer Care (Engl). 2016 May;25(3):458-65. doi: 10.1111/ecc.12460. Epub 2016 Feb 18. Eur J Cancer Care (Engl). 2016. PMID: 26891443
Dispersive flight by Triatoma sordida.
Schofield CJ, Lehane MJ, McEwan P, Catalá SS, Gorla DE. Schofield CJ, et al. Among authors: catala ss. Trans R Soc Trop Med Hyg. 1991 Sep-Oct;85(5):676-8. doi: 10.1016/0035-9203(91)90392-c. Trans R Soc Trop Med Hyg. 1991. PMID: 1781007
Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group.
Hober C, Fredeau L, Pham-Ledard A, Boubaya M, Herms F, Celerier P, Aubin F, Beneton N, Dinulescu M, Jannic A, Meyer N, Duval-Modeste AB, Cesaire L, Neidhardt ÈM, Archier É, Dréno B, Lesage C, Berthin C, Kramkimel N, Grange F, de Quatrebarbes J, Stoebner PE, Poulalhon N, Arnault JP, Abed S, Bonniaud B, Darras S, Heidelberger V, Devaux S, Moncourier M, Misery L, Mansard S, Etienne M, Brunet-Possenti F, Jacobzone C, Lesbazeilles R, Skowron F, Sanchez J, Catala S, Samimi M, Tazi Y, Spaeth D, Gaudy-Marqueste C, Collard O, Triller R, Pracht M, Dumas M, Peuvrel L, Combe P, Lauche O, Guillet P, Reguerre Y, Kupfer-Bessaguet I, Solub D, Schoeffler A, Bedane C, Quéreux G, Dalac S, Mortier L, Maubec È. Hober C, et al. Among authors: catala s. Cancers (Basel). 2021 Jul 15;13(14):3547. doi: 10.3390/cancers13143547. Cancers (Basel). 2021. PMID: 34298764 Free PMC article.
93 results